A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
DRUG: Bevacizumab
DRUG: Entinostat
DRUG: Exemestane
DRUG: Fulvestrant
DRUG: Ipatasertib
DRUG: Tamoxifen
DRUG: Abemaciclib

Sponsor

Hoffmann-La Roche